Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;11(3):180-185.
doi: 10.1016/j.prnil.2023.07.003. Epub 2023 Jul 20.

Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men

Affiliations

Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men

Shuji Isotani et al. Prostate Int. 2023 Sep.

Abstract

Objectives: To investigate the role of urine spermine and spermine risk score in predicting prostate cancer (PCa) diagnoses in combination with multiparametric magnetic resonance imaging (mpMRI).

Methods: Three hundred forty seven consecutive men with elevated prostate-specific antigen (PSA) with mpMRI examination were prospectively enrolled in this study. In 265 patients with PSA levels between 4 and20 ng/ml, pre-biopsy urine samples were analyzed for spermine levels with ultra-high performance liquid chromatography (UPLC-MS/MS). Transperineal image-guided prostate biopsies with 16-18 cores were performed. Logistic regressions were used to form different models for the prediction of the PCa, and the performances were compared using the area under the curve (AUC).

Results: The median serum PSA level and prostate volume were 7.4 ng/mL and 33.9 mL, respectively. PCa and high-grade PCa (ISUP group ≥2, HGPCa) were diagnosed in 66.0% (175/265) and 132/265 (49.8%) cases, respectively. The urine spermine levels were significantly lower in men with PCa (0.87 vs. 2.20, P < 0.001). Multivariate analyses showed that age, PSA, PV, urine spermine level, and Prostate Imaging Reporting and Data System (PI-RADS) findings were independent predictors for PCa. The Spermine Risk Score is a multivariable model including PSA, age, prostate volume, and urine spermine. Adding the Spermine Risk Score to PI-RADS improved the AUC from 0.73 to 0.86 in PCa and from 0.72 to 0.83 in high grade PCa (HGPCa) prediction (both P < 0.001). At 90% sensitivity for HGPCa prediction using Spermine Risk Score, 31.1% of unnecessary biopsies could be avoided. In men with equivocal MRI PI-RADS score 3, the AUC for HGPCa prediction was 0.58, 0.79, and 0.87 for PSA, PSA density, and Spermine Risk Score, respectively.

Conclusion: Urine Spermine Risk Score, including mpMRI could accurately identify men at high risk of HGPCa and reduce unnecessary prostate biopsies. Spermine Risk Score could more accurately predict HGPCa than PSA density in men with MRI showing equivocal PI-RADS 3 lesions.

Keywords: Biomarker; Multiparametric MRI; Prostate cancer; Urine spermine.

PubMed Disclaimer

Conflict of interest statement

KL Wong holds a patent for urinary polyamines as prostate cancer detection biomarkers (patent no. US20180172695A1). This does not alter our adherence to “prostate international” policies on sharing data and materials. The other authors declare that they have no conflicts of interest.

Figures

Figure 1
Fig. 1
Areas under the curve of the calculated probabilities of prediction of the prostate cancer.
Figure 2
Fig. 2
Internal validation with bootstrapping. a. any grade of prostate cancer predicted by PSA, normalized spermine, age, prostate volume, and PI-RADS score. b. high grade prostate cancer predicted by PSA, normalized spermine, age, prostate volume, and PI-RADS score.

Similar articles

Cited by

References

    1. Suzuki K. Epidemiology of prostate cancer and benign prostatic hyperplasia. J Jpn Med Assoc. 2009;138(2):251–254.
    1. Gulati R., Gore J.L., Etzioni R. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145–153. - PMC - PubMed
    1. Ito K., Yamamoto T., Kubota Y., Suzuki K., Fukabori Y., Kurokawa K., et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology. 2000;56(2):278–282. - PubMed
    1. AUA Prostate-specific antigen (PSA) best practice policy. Oncology (Huntingt) 2000;14:280. - PubMed
    1. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Zappa M., Nelen V., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. - PMC - PubMed